HomeAI · summaries
Storia in 3 fonti
Ionis scores transformational FDA label expansion for Tryngolza
After 35 years engaged in the research and development of pharmaceutical products, Ionis began marketing its drugs for the first time in 2024. | Ionis has gained an FDA expansion for Tryngolza to become the first treatment specifically approved for severe hypertriglyceridemia. The nod will significantly increase the revenue-generating potential of the antisense oligonucleotide drug.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Ionis wins FDA label expansion for potential blockbuster triglycerides indication
Ionis wins FDA approval to expand Tryngolza into severe hypertriglyceridemia, a far larger market than its rare FCS launch, with peak US sales seen topping $3B.
- ·
fiercepharma.com
Ionis scores transformational FDA label expansion for Tryngolza
After 35 years engaged in the research and development of pharmaceutical products, Ionis began marketing its drugs for the first time in 2024. | Ionis has gained an FDA expansion…
